US · TMO
Thermo Fisher Scientific Inc.
- Sector
- Healthcare · Medical - Diagnostics & Research
- Headquarters
- Waltham, MA 02451
- Website
- thermofisher.com
Price · as of 2025-12-31
$469.21
Market cap 195.79B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $336.03 | -28.38% |
| Intrinsic Value(DCF) | $210.02 | -55.24% |
| Graham-Dodd Method(GD) | $75.00 | -84.02% |
| Graham Formula(GF) | $214.23 | -54.34% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $53.29 | $60.76 | $0.00 | $25.47 | $57.12 |
| 2012 | $73.65 | $78.81 | $0.00 | $18.55 | $46.77 |
| 2013 | $121.93 | $111.57 | $16.07 | $20.75 | $44.28 |
| 2014 | $123.24 | $116.14 | $6.23 | $19.23 | $170.65 |
| 2015 | $136.26 | $119.93 | $1.86 | $22.05 | $42.18 |
| 2016 | $155.47 | $136.01 | $0.00 | $17.08 | $79.84 |
| 2017 | $213.33 | $168.32 | $8.35 | $19.48 | $123.39 |
| 2018 | $245.35 | $192.18 | $57.07 | $32.19 | $174.07 |
| 2019 | $306.37 | $225.61 | $145.37 | $44.97 | $117.55 |
| 2020 | $444.61 | $330.62 | $1,043.26 | $89.11 | $534.33 |
| 2021 | $523.95 | $386.31 | $529.62 | $80.12 | $568.25 |
| 2022 | $539.00 | $359.15 | $557.74 | $78.33 | $391.75 |
| 2023 | $593.89 | $381.29 | $18.72 | $64.36 | $57.94 |
| 2024 | $529.84 | $378.27 | $8.22 | $69.79 | $134.83 |
| 2025 | $508.58 | $336.03 | $19.27 | $75.00 | $214.23 |
AI valuation
Our deep-learning model estimates Thermo Fisher Scientific Inc.'s (TMO) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $336.03
- Current price
- $469.21
- AI upside
- -28.38%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$210.02
-55.24% upside
Graham-Dodd
$75.00
-84.02% upside
Graham Formula
$214.23
-54.34% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| TMO | Thermo Fisher Scientific … | $469.21 | 195.79B | -28% | -55% | -84% | -54% | 28.45 | 3.58 | 4.29 | 19.23 | 388.69 | -16.23 | 37.66% | 18.20% | 15.12% | 13.05% | 9.40% | 6.47% | 0.74 | 5.71 | 1.89 | 1.25 | 2.58 | 732.00% | 391.00% | -1340.00% | 3.29% | 0.51 | 7.89% | 0.33% | 9.50% | 1.90% | 27.19 | 35.04 | 4.95 | 2.81 |
| A | Agilent Technologies, Inc… | $121.38 | 34.41B | -21% | -48% | -87% | -44% | 96.67 | 6.22 | 6.04 | 23.72 | 3059.02 | 23.01 | 52.43% | 21.29% | 18.75% | 6.87% | 16.33% | 3.53% | 0.50 | 13.21 | 1.96 | 1.40 | 0.85 | 316.00% | 673.00% | -1610.00% | 2.75% | 0.66 | 14.01% | 0.67% | 65.00% | 3.31% | 29.43 | 37.78 | 6.26 | 5.50 |
| ABT | Abbott Laboratories | $116.32 | 202.45B | -26% | -58% | — | -57% | 30.56 | 3.82 | 4.50 | 17.79 | — | 8.83 | 55.51% | 18.16% | 14.72% | 13.07% | 10.95% | 7.76% | 0.29 | 23.60 | 1.58 | 1.02 | 0.57 | -5131.00% | 567.00% | 1644.00% | 3.71% | 0.58 | 13.06% | 2.06% | 63.10% | 3.07% | 25.53 | 27.79 | 4.64 | 5.28 |
| AMGN | Amgen Inc. | $387.96 | 209.14B | -9% | -34% | — | -35% | 26.91 | 23.97 | 5.65 | 15.97 | 30.50 | -6.42 | 70.80% | 29.06% | 20.99% | 106.10% | 16.96% | 8.45% | 6.31 | 3.88 | 1.14 | 0.73 | 2.87 | 8823.00% | 992.00% | -2207.00% | 3.90% | 0.39 | 14.98% | 2.47% | 66.50% | 3.75% | 23.70 | 31.23 | 6.89 | 2.36 |
| AZN | AstraZeneca PLC | $208.45 | 646.31B | -44% | -57% | -100% | -74% | 61.77 | 12.98 | 10.75 | 33.06 | 32.62 | -60.60 | 81.90% | 23.40% | 17.46% | 22.86% | 16.43% | 9.38% | 0.61 | 8.11 | 0.94 | 0.68 | 1.21 | 18938.00% | 863.00% | 6172.00% | 1.86% | 0.48 | 17.05% | 0.80% | 49.70% | 1.02% | 47.70 | 55.72 | 11.16 | 6.83 |
| DHR | Danaher Corporation | $210.64 | 148.95B | -10% | -58% | -90% | -73% | 40.32 | 2.77 | 5.93 | 22.97 | — | -17.28 | 60.93% | 20.91% | 14.71% | 7.08% | 6.70% | 4.49% | 0.35 | 19.38 | 1.87 | 1.25 | 1.99 | -473.00% | 290.00% | -68.00% | 3.61% | 0.94 | 8.03% | 0.60% | 24.30% | 3.59% | 31.05 | 30.32 | 6.49 | 4.20 |
| IQV | IQVIA Holdings Inc. | $178.81 | 30.45B | -2% | -53% | — | -39% | 22.01 | 4.61 | 1.84 | 12.70 | 471.04 | -1.99 | 26.28% | 14.02% | 8.34% | 21.65% | 9.92% | 4.79% | 2.49 | 3.14 | 0.75 | 0.67 | 4.10 | 467.00% | 587.00% | -298.00% | 6.85% | 0.32 | 10.54% | 0.00% | 0.00% | 4.15% | 19.23 | 21.45 | 2.70 | 1.83 |
| ISRG | Intuitive Surgical, Inc. | $503.51 | 178.81B | -37% | -41% | -82% | -56% | 61.57 | 9.94 | 17.60 | 47.34 | 272.61 | 10.15 | 66.00% | 29.27% | 28.38% | 16.79% | 20.67% | 14.58% | 0.02 | — | 4.87 | 3.77 | -0.85 | 2259.00% | 2051.00% | 9103.00% | 1.41% | 1.51 | 20.12% | 0.00% | 0.00% | 1.96% | 58.22 | 68.85 | 17.04 | 41.40 |
| MRK | Merck & Co., Inc. | $123.78 | 306.03B | +5% | -27% | -61% | -44% | 16.68 | 5.79 | 4.68 | 13.42 | 208.16 | 70.05 | 81.50% | 41.19% | 28.08% | 36.91% | 29.12% | 17.40% | 0.96 | — | 1.54 | 0.96 | 1.42 | 801.00% | 131.00% | -10000.00% | 0.00% | 0.00 | 0.00% | 0.00% | 0.00% | 0.00% | 12.71 | — | 5.24 | 5.12 |
| NVO | Novo Nordisk A/S | $37.45 | 166.46B | +59% | +7% | — | -3% | 10.46 | 5.52 | 3.60 | 8.17 | 591.70 | 16.74 | 80.34% | 43.69% | 33.14% | 60.70% | 39.34% | 20.31% | 0.67 | 19.92 | 0.80 | 0.48 | 0.73 | 177.00% | 234.00% | -5838.00% | 2.71% | 0.55 | 11.19% | 4.65% | 48.60% | 4.77% | 9.05 | 40.54 | 3.95 | 3.59 |
| NVS | Novartis AG | $168.62 | 325.95B | -29% | -50% | — | -40% | 23.02 | 7.01 | 5.90 | 15.18 | 102.37 | -36.57 | 75.02% | 31.15% | 25.64% | 31.17% | 21.84% | 12.91% | 0.80 | 14.38 | 1.12 | 0.83 | 1.11 | 2249.00% | 597.00% | 2811.00% | 5.47% | 0.71 | 26.49% | 2.43% | 55.90% | 5.29% | 20.44 | 19.73 | 6.37 | 4.35 |
About Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.
- CEO
- Marc N. Casper
- Employees
- 125K
- Beta
- 0.95
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($210.02 ÷ $469.21) − 1 = -55.24% (DCF, example).